Acumen Pharmaceuticals (NASDAQ:ABOS) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Acumen Pharmaceuticals (NASDAQ:ABOS) released its quarterly earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same quarter last year, the business posted ($0.28) earnings per share.

Acumen Pharmaceuticals Stock Down 2.6 %

Acumen Pharmaceuticals stock traded down $0.10 during trading hours on Wednesday, hitting $3.71. The company had a trading volume of 40,325 shares, compared to its average volume of 333,722. Acumen Pharmaceuticals has a fifty-two week low of $1.81 and a fifty-two week high of $11.31. The company has a debt-to-equity ratio of 0.12, a current ratio of 30.20 and a quick ratio of 30.20. The firm has a market capitalization of $222.90 million, a P/E ratio of -3.52 and a beta of 0.19. The firm’s fifty day moving average is $3.69 and its 200-day moving average is $3.40.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Acumen Pharmaceuticals in a report on Wednesday, May 15th.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers.